Mettrum Health Corp. Launches Premium Cannabis Oils Product Line
Variety of THC and CBD oils addresses demand for alternative cannabis consumption options
TORONTO, Jan. 26, 2016 /CNW/ – Mettrum Health Corp. (“Mettrum” or the “Company”) (TSXV:MT), a fully-integrated licensed producer (LP) of premium cannabis products, launched its much-anticipated line of Mettrum Cannabis Oils today.
Mettrum Cannabis Oils will be priced at $90 for one 40 ml bottle, which contains the equivalent medicinal content of five grams of dried marijuana. Mettrum produces whole-flower cannabis extracts using state-of-the art supercritical fluid CO2 extraction technology. The process extracts the major cannabinoids (THC and CBD), as well as the minor cannabinoids, terpenes and flavonoids that contribute to the overall medicinal value of medical cannabis. The result of this process is a highly concentrated resin. This extract is then suspended in an oil to make it easier to administer orally. Mettrum uses medium chain triglyceride oil (MCT) in our formulations. MCT is naturally occurring and used widely in the food, pharmaceutical and natural products industry. It is highly stable, flavourless, odourless, and allows for increased absorption making it ideal to use in cannabis oils.
“As Canada’s second LP to receive a license to sell cannabis extracts, we’ve been working hard to deliver accessibly priced, premium oils for our clients,” said Michael Haines, CEO of Mettrum. “We are responding to the demand from patients and health care professionals alike for alternative consumption methods of medical cannabis.”
Today, Mettrum is launching three oils in the Red, Blue, and Yellow categories, in line with the Mettrum Spectrum™, a trademarked system that helps physicians and their patients select the cannabis strain or strains that are most appropriate for their particular medical need. The Mettrum Spectrum™ allows for the categorization of medical cannabis products based on different ratios of key medicinal cannabinoids: cannabidiol (CBD) and tetrahydrocannabinol (THC). The Blue and Yellow category oils are notably unique as they are derived from rare strains of cannabis with a high ratio of CBD to THC ̶ making them a relevant treatment for an expanded population of prospective patients. In the coming weeks, additional products will be added to broaden the selection across the categories that make up the Mettrum Spectrum™.
The launch comes on the heels of the announcement that Mettrum received a license from Health Canada for the production of cannabis at its new 60,000-square-foot production facility in Bowmanville, Ontario.
“The new facility gives us the production capacity to fulfill clients’ needs in a fast-growing sector, while still producing the premium products that they have come to expect from us,” said Haines. “We’re pleased to be able to provide our clients with consistent supply of our full range of products at all times.”
About Mettrum Cannabis Oils
Mettrum produces cannabis oils with different ratios of the major cannabinoids (THC and CBD) to meet client’s unique medical needs. The Mettrum Spectrum™ categorization of cannabis simplifies the choice of oil by creating parity between the composition of dried marijuana and the related oil.
About the Mettrum Spectrum™
The Mettrum Spectrum™ is designed to simplify the dialogue around medical cannabis by categorizing Mettrum strains according to THC and CBD levels, using a straightforward, colour-coded system. The adoption of the Mettrum Spectrum™, allows health care practitioners to recommend strains to their patients with confidence.
About Mettrum Health Corp
Mettrum Health Corp. is a Tier-1 Industry Issuer listed on TSX Venture Exchange. Mettrum Ltd., a wholly owned subsidiary, is aToronto-based company and licensed producer of medical cannabis under the Marihuana for Medical Purposes Regulations (Canada)issued pursuant to the Controlled Drugs and Substances Act (Canada) (MMPR). The Company is a leading producer and vendor of medical cannabis under the MMPR system and has three licensed production facilities totalling 85,000 square feet representing annual production capacity of approximately 12,000 kilograms.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive board, shareholder or regulatory approvals; and the results of operations. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company and Mettrum disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this Press release.
SOURCE Mettrum Health Corp.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.